The Biopharmaceutical Company focused on the biology of healing has over recent days provided encouraging updates on both its plasma derived therapeutics programme and on the development of its small molecule portfolio. Yesterday ProMetic has announced that the FDA has granted a Fast Track designation to ProMetic’s Plasminogen drug candidate, currently in a phase 2/3 clinical trial in patients suffering from congenital Plasminogen deficiency. The rolling review should greatly enhance th
